Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

2.

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI.

J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8.

PMID:
19064974
3.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ.

J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.

4.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr├╝nwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group..

Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.

PMID:
18653228
5.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators..

Lancet. 2007 Dec 22;370(9605):2103-11.

PMID:
18156031
6.
7.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial..

N Engl J Med. 2007 May 31;356(22):2271-81.

8.

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.

Cancer. 2007 Jun 1;109(11):2257-67.

9.

Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.

Tickoo SK, Alden D, Olgac S, Fine SW, Russo P, Kondagunta GV, Motzer RJ, Reuter VE.

J Urol. 2007 Apr;177(4):1258-63.

PMID:
17382701
10.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group..

N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.

11.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

12.

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH.

J Surg Oncol. 2007 Mar 15;95(4):317-23.

PMID:
17066434
13.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
14.

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.

Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP.

Cancer. 2004 Oct 1;101(7):1545-51.

15.

Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ.

J Clin Oncol. 2004 Sep 15;22(18):3720-5.

PMID:
15365068
16.

Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.

Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML.

Am J Surg Pathol. 2004 Apr;28(4):435-41.

PMID:
15087662
17.

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M.

Invest New Drugs. 2003 Feb;21(1):99-101.

PMID:
12795534
18.

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S; Genitourinary Group of the French Federation of Cancer Centers..

J Urol. 2002 Sep;168(3):959-61.

PMID:
12187199
19.

Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.

de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB.

Am J Surg Pathol. 2001 Mar;25(3):275-84.

PMID:
11224597
20.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J.

J Clin Oncol. 1999 Aug;17(8):2530-40.

PMID:
10561319

Supplemental Content

Support Center